Cuprina Holdings (Cayman) Limited (CUPR)
NASDAQ: CUPR ยท Real-Time Price ยท USD
1.600
-0.090 (-5.33%)
Nov 18, 2026, 4:00 PM EST - Market closed
CUPR Revenue
In the year 2025, Cuprina Holdings (Cayman) Limited had annual revenue of 49.89K SGD with 3.26% growth. Cuprina Holdings (Cayman) Limited had revenue of 26.88K in the half year ending December 31, 2025, a decrease of -52.07%. That makes Cuprina Holdings (Cayman) Limited the 46,713th largest company in the world by revenue and 6,999th in the United States.
Revenue (ttm)
49.89K SGD
Revenue Growth
+3.26%
P/S Ratio
288.88
Revenue / Employee
4,989 SGD
Employees
10
Market Cap
11.21M USD
Revenue by Segment
- Maggot Debridement Therapy Product 44.20K 88.6%
- Cosmeceutical Product 5.69K 11.4%
Fiscal year ended Dec 31, 2025 See the full CUPR breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 49.89K | 1.57K | 3.26% |
| Dec 31, 2024 | 48.32K | -52.45K | -52.05% |
| Dec 31, 2023 | 100.77K | 44.17K | 78.05% |
| Dec 31, 2022 | 56.60K | -1.91K | -3.26% |
| Dec 31, 2021 | 58.50K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Harvard Bioscience | 89.41M |
| Retractable Technologies | 33.90M |
| Precision Optics Corporation | 31.53M |
| Bionano Genomics | 31.09M |
| Nephros | 21.58M |
| Milestone Scientific | 9.28M |
| Lucyd | 3.75M |
| Femasys | 1.97M |
CUPR News
- 6 weeks ago - Cuprina (Nasdaq: CUPR) to Acquire EBITDA-Positive Seven-Clinic Singapore Healthcare Group - GlobeNewsWire
- 7 weeks ago - Cuprina Holdings (Cayman) Limited Announces Closing of Underwriter's Over-Allotment Option in Connection with Public Offering - GlobeNewsWire
- 2 months ago - Cuprina Holdings (Cayman) Limited Announces Closing of Public Offering - GlobeNewsWire
- 5 months ago - Cuprina Holdings receives FDA clearance for Medifly Maggots - TheFly
- 5 months ago - Cuprina Receives U.S. FDA 510(k) Clearance for MEDIFLY Maggots โ the First U.S. Clearance for a Lucilia cuprina Maggot Debridement Product - GlobeNewsWire
- 5 months ago - Cuprina Holdings regains compliance with Nasdaq - TheFly
- 5 months ago - Cuprina Holdings (Cayman) Limited Regains Compliance with Nasdaq Listing Requirements - GlobeNewsWire
- 5 months ago - Cuprina Holdings completes reverse stock split, requests Nasdaq panel hearing - TheFly